# US 2017/0281657 A1 · Low Osmolality Gel Composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281657 A1
- Document ID: US20170281657A1
- Status: Published application
- Kind: A1
- Application number: 15/478,942
- Filed: 2017-04-04
- Published: 2017-10-05
- Earliest claimed: 2016-04-04
- Assignees: ImQuest BioSciences, Inc.
- Applicants: ImQuest BioSciences, Inc.
- Inventors: Robert W. Buckheit, JR.; Anthony Sang Won Ham
- Web page: https://patentgrep.com/patent/US20170281657A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0036: {Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to polymer gel compositions and more specifically to polymer gel compositions having low osmolality for use on rectal mucosa. The present invention extends to their methods of manufacture and use, including as drug delivery vehicles and personal lubricants.

## Claims

### Claim 1

A personal lubricant composition comprising at least one water soluble polyhydric alcohol and at least one water-soluble polymer derived from cellulose, wherein the personal lubricant has an osmolality between about 200 mOsm/kg and about 500 mOsm/kg and a pH of about 7 or less.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the personal lubricant has an osmolality between about 200 mOsm/kg and about 350 mOsm/kg.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the personal lubricant has an osmolality of about 200 mOsm/kg, about 220 mOsm/kg, about 240 mOsm/kg, about 260 mOsm/kg, about 280 mOsm/kg, about 300 mOsm/kg, about 320, mOsm/kg, about 350 mOsm/kg, about 360 mOsm/kg, about 380 mOsm/kg or about 400 mOsm/kg.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the personal lubricant has a pH of between about 5.8 and about 6.2.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the personal lubricant has an osmolality between about 200 mOsm/kg and about 300 mOsm/kg and a pH between about 5.5 and about 6.5.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the personal lubricant has a viscosity of between about 4 and about 5 Pa·s.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the water soluble polyhydric alcohol is glycerol and the water-soluble polymer is hydroxyethyl cellulose.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the personal lubricant further comprises a paraben preservative.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the personal lubricant comprises about 1 to about 3 weight percent of the water-soluble polyhydric alcohol.

### Claim 10 (depends on 1)

A method of personal lubrication, comprising applying a personal lubricant composition of claim 1 to a body part in need thereof.

### Claim 11

A microbicide composition comprising at least one water-soluble polyhydric alcohol, at least one water-soluble polymer derived from cellulose and at least one antimicrobial agent, wherein the microbicide composition has an osmolality between about 200 mOsm/kg and about 500 mOsm/kg and a pH of about 7 or less.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the microbicide composition has an osmolality between about 200 mOsm/kg and about 350 mOsm/kg.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the microbicide composition has a pH of between about 5.8 and about 6.2.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the microbicide composition has an osmolality between about 200 mOsm/kg and about 300 mOsm/kg and a pH between about 5.5 and about 6.5.

### Claim 15 (depends on 11)

The composition of claim 11, wherein the microbicide composition has a viscosity of between about 4 and about 5 Pa·s.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the at least one antimicrobial agent is selected from the group consisting of anti-viral agents, anti-bacterial agents, anti-fungal agents or combinations thereof.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the anti-viral agent is selected from the group consisting of protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, entry inhibitors, maturation inhibitors and pharmaceutically-acceptable salts and precursors thereof.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the anti-viral agent is tenofovir.

### Claim 19 (depends on 16)

The composition of claim 16, wherein the anti-viral agent is IQP-0528.

### Claim 20 (depends on 11)

The composition of claim 11, wherein the microbicide composition further comprises a rheology modifier Carbopol®.

### Claim 21 (depends on 11)

The composition of claim 11, wherein the microbicide composition further comprises a chelator agent.

### Claim 22 (depends on 11)

A method of reducing or preventing transmission of a sexually transmitted disease, comprising applying the microbicide composition of claim 11 to a body part in need thereof.

### Claim 23

A rectal drug delivery vehicle comprising at least one water-soluble polyhydric alcohol, a water-soluble polymer derived from cellulose and at least one antimicrobial agent, wherein the drug delivery vehicle has an osmolality between about 200 mOsm/kg and about 500 mOsm/kg and a pH of about 7 or less.

### Claim 24 (depends on 1, 11)

A pharmaceutical composition comprising the composition of claim 1 or 11 and at least one therapeutic agent, wherein the pharmaceutical composition has an osmolality between about 200 mOsm/kg and about 500 mOsm/kg and a pH of about 7 or less.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the at least one therapeutic agent is selected from a buffering agent, a contraceptive agent, a anticonvulsants, non-narcotic analgesics and non-steroidal anti-inflammatory agents, hypnosedatives and anaesthetics, strong analgesics, theophylline and derivatives, corticosteroids, antibacterial agents, thiazinamium, promethazine, hyoscine-N-butyl-bromide, streptokinase, progesterone, ergotamine tartrate, levodopa and combinations thereof.

### Claim 26

A method of manufacturing a composition, comprising the steps of:
a) preparing an aqueous buffered solution and separating into a first and second portion,
b) combining polyhydric alcohol and preservatives in a vial, heating to dissolution and cooling to room temperature,
c) adding the mixture from step (ii) to the first portion of buffered solution while stirring,
d) adding a volume of the second portion of buffered solution to the vial from step (d), mixing and adding the volume to the stirring first portion of the buffered solution and repeating step (iv) with all of the second portion of buffered solution
e) gradually adding water-soluble cellulosic polymer to buffered solution and continue stirring until homogeneous, and
f) adjusting pH to about 5.0 to 7.0.
